AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
74.19
-0.38 (-0.50%)
Feb 21, 2025, 3:07 PM EST - Market open
AstraZeneca Employees
AstraZeneca had 92,900 employees as of December 31, 2024. The number of employees increased by 3,000 or 3.34% compared to the previous year.
Employees
92,900
Change (1Y)
3,000
Growth (1Y)
3.34%
Revenue / Employee
$582,056
Profits / Employee
$75,727
Market Cap
229.50B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 92,900 | 3,000 | 3.34% |
Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
Dec 31, 2022 | 83,500 | 400 | 0.48% |
Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
Dec 31, 2019 | 70,600 | 6,000 | 9.29% |
Dec 31, 2018 | 64,600 | 3,500 | 5.73% |
Dec 31, 2017 | 61,100 | 1,400 | 2.35% |
Dec 31, 2016 | 59,700 | -1,800 | -2.93% |
Dec 31, 2015 | 61,500 | 4,000 | 6.96% |
Dec 31, 2014 | 57,500 | 6,000 | 11.65% |
Dec 31, 2013 | 51,500 | -200 | -0.39% |
Dec 31, 2012 | 51,700 | -5,500 | -9.62% |
Dec 31, 2011 | 57,200 | -3,800 | -6.23% |
Dec 31, 2010 | 61,000 | -1,700 | -2.71% |
Dec 31, 2009 | 62,700 | -2,300 | -3.54% |
Dec 31, 2008 | 65,000 | -2,400 | -3.56% |
Dec 31, 2007 | 67,400 | 600 | 0.90% |
Dec 31, 2006 | 66,800 | 1,500 | 2.30% |
Dec 31, 2005 | 65,300 | 1,100 | 1.71% |
Dec 31, 2004 | 64,200 | 1,600 | 2.56% |
Dec 31, 2003 | 62,600 | 3,400 | 5.74% |
Dec 31, 2002 | 59,200 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
AbbVie | 55,000 |
AZN News
- 23 hours ago - Final Deadline for the AstraZeneca PLC Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - AZN - PRNewsWire
- 1 day ago - AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline - Investopedia
- 1 day ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit – AZN - GlobeNewsWire
- 1 day ago - Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million - Benzinga
- 1 day ago - FibroGen sells China unit to AstraZeneca in deal worth $160 million - Reuters
- 2 days ago - AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold - Seeking Alpha
- 2 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca - GlobeNewsWire
- 5 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca - Accesswire